Tysabri® Biosim approved under REMS program In June 2023, the US district court’s rejection in Biogen vs Sandoz’s Tysabri®’s patent infringement case where Biogen alleged
Stelara® Biosimilars: Relief for plaque psoriasis patients Johnson & Johnson’s (J&J) plaque psoriasis blockbuster drug, Stelara® (Ustekinumab), gained its first approval from U.S. FDA in September 2009.
Maximizing Innovation Lifespans: Canada Patent Term Adjustment To commit to Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada introduced Certificate of Supplementary Protection
Preventing Delays in Generic Drug Entry Generic drugs are identical to their brand-name counterparts in safety, effectiveness, strength, and quality. Also, they offer the same therapeutic
Competitive Generic Therapy – A Boon for Complex Pharmaceutical Drugs Often drugs which are difficult to mass produce and have limited market potential as well
Patent Term Extensions – A Lifeline to the Pharmaceutical Innovation 1. What are Patent Term Extensions? How do they differ from Supplementary Protection Certificates?
